A randomised clinical trial of awake prone positioning in COVID-19 suspects with acute hypoxemic respiratory failure

Abstract

BackgroundAwake prone position (APP) has been reported to improve oxygenation in patients with COVID-19 disease and to reduce the requirement for invasive mechanical ventilation for patients requiring support with high flow nasal cannula.There is conflicting data for patients requiring lower-level oxygen support. Research questionDoes APP reduce escalation of oxygen support in COVID-19 patients requiring supplementary oxygen?The primary outcome was defined as an escalation of oxygen support from simple supplementary oxygen (NP, HM, NRB) to NIV (CPAP or BiPAP), HFNC or IMV; OR from NIV (CPAP or BiPAP) or HFNC to IMV by day30. Study designTwo center, prospective, non-blind, randomised controlled trial.Patients with confirmed or suspected COVID-19 pneumonia requiring ≥ 5 liters/minute oxygen to maintain saturations ≥ 94 % were randomised to either APP or control group.The APP group received a three-hour APP session three times per day for three days. ResultsBetween 9 May and 13 July 2021, 89 adults were screened and 61 enrolled, 31 to awake prone position and 30 controls.There was no difference in the primary outcome, 7 (22.6 %) patients randomised to APP and 9 (30.0 %) controls required escalation of oxygen support (OR 0.68 (0.22–2.14), P = 0.51).There were no differences in any secondary outcomes, in APP did not improve oxygenation. InterpretationIn COVID-19 patients, the use of APP did not prevent escalation of oxygen support from supplementary to invasive or non-invasive ventilation or improve patient respiratory physiology. Trial registrationNCT04853979 (clinicaltrials.gov).